GlassScriptPhysician profile
Brian J Kolender
NPI 1417931015
$5,411.66
in general payments reported to CMS, 2019-2025
29 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $781 · 2021: $1,143 · 2022: $655 · 2023: $973 · 2024: $469 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,204.06 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $1,018.54 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $616.17 | 2019-2022 | |
| Lilly USA, LLC | $470.91 | 2020-2023 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $451.07 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $235.66 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.75 | 2020-2023 | Spiriva Respimat |
| Glaxosmithkline, LLC. | $176.37 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $133.15 | 2019-2025 | |
| Pfizer INC. | $115.26 | 2020-2024 | |
| Heartflow, INC. | $107.97 | 2023 | Ffrct |
| Abbvie INC. | $105.48 | 2021-2024 | |
| Exact Sciences Corporation | $77.79 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $58.61 | 2021-2025 | Nexletol |
| Dexcom, INC. | $52.26 | 2022-2023 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $49.17 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $46.43 | 2021 | |
| Horizon Therapeutics Plc | $32.18 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $29.07 | 2021-2023 | |
| Solta Medical, A Division of Bausch Health US, LLC | $24.76 | 2024 | Clear+Brilliant |
| Avanir Pharmaceuticals, INC. | $21.28 | 2020 | |
| Astellas Pharma US INC | $20.85 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $20.31 | 2024 | Rhythm Express |
| Shield Therapeutics INC | $20.18 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.49 | 2022 | |
| Corcept Therapeutics | $17.43 | 2023 | Korlym |
| Electromed, INC. | $15.77 | 2022 | |
| Biomerieux INC | $14.00 | 2025 | Biofire Spotfire Control Station |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kolender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.